Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Parnax LabBOM:506128 -2.32%69 EBITDA Margin % is 9.55% as of Mar. 2026, which is 23% below its 10-year median of 12.40. GuruFocus rates BOM:506128 with a GF Score™ of 69/100 and a GF Value™ of ₹149.14 (Fairly Valued). The stock has 4 warning signs investors should review. Among 961 Drug Manufacturers companies, Parnax Lab ranks worse than 51.2% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Parnax Lab's EBITDA for the
three
months ended in Mar. 2026 was ₹66 Mil. Parnax Lab's Revenue for the
three
months ended in Mar. 2026 was ₹696 Mil. Therefore, Parnax Lab's EBITDA margin for the quarter that ended in Mar. 2026 was 9.55%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Parnax Lab EBITDA Margin % Related Terms
Parnax Lab EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Parnax Lab's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Parnax Lab's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Parnax Lab EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Parnax Lab's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Parnax Lab's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Parnax Lab (BOM:506128) has a EBITDA Margin % of 9.55% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Parnax Lab and its competitors. This is 23% below median its historical median of 12.40. Over the past decade, Parnax Lab's EBITDA Margin % has ranged from 7.29 to 15.15. According to the industry distribution chart, Parnax Lab ranks #492 out of 961 companies in the Drug Manufacturers industry, placing it in the top 51.2%.
Is Parnax Lab's EBITDA Margin % too high?
Parnax Lab's current EBITDA Margin % of 9.55% is 23% below median its 10-year median of 12.40. Over the past 10 years, this metric has ranged from a low of 7.29 to a high of 15.15. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Parnax Lab's value of 9.55% is 23.2% below this industry median. Based on the distribution chart, Parnax Lab ranks #492 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Parnax Lab has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Parnax Lab's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Parnax Lab ranks #492 out of 961 companies for EBITDA Margin %. This places Parnax Lab in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Parnax Lab's value of 9.55% is 23.2% below this benchmark. Historically, Parnax Lab's own EBITDA Margin % has ranged from 7.29 to 15.15 over the past decade. While the company's 10-year median is 12.40 vs. the industry median of 12.44, Parnax Lab has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Parnax Lab's current EBITDA Margin % of 9.55% is 23.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Parnax Lab and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Parnax Lab's current EBITDA Margin % is 9.55%, which is 23% below median its own 10-year median of 12.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Parnax Lab stock overvalued right now?
Based on GuruFocus' analysis, Parnax Lab (BOM:506128) is currently considered Fairly Valued. The stock's GF Value™ is ₹149.14, compared to a current price of ₹135.00 — trading 9.5% below its estimated fair value. The current EBITDA Margin % is 9.55%, which is 23% below median its 10-year median of 12.40 and 23.2% below the Drug Manufacturers industry median of 12.44. Parnax Lab's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Parnax Lab (BOM:506128), the current EBITDA Margin % is 9.55% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Parnax Lab (BOM:506128) Overvalued in 2026?
Based on GuruFocus' analysis, Parnax Lab stock appears to be undervalued.
The current stock price of ₹135.00 is trading 9.5% below its estimated GF Value™ of ₹149.14.
GuruFocus considers Parnax Lab to be Fairly Valued.
Key valuation signals for BOM:506128:
EBITDA Margin %: 9.55% (23% below median its 10-year median of 12.40)
GF Value™: ₹149.14 vs. price of ₹135.00 (9.5% below fair value)
Industry Position: 23.2% below the Drug Manufacturers median (#492 of 961)
No single metric tells the full story. See the BOM:506128 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Address104 - 107, Building No. 8, Gala No. 114, Jogani Industrial Complex, Panchsheel Nagar, Next to Modi Hyundai Service Centre, Chunabhatti, Sion, Mumbai, MH, IND, 400 022
Parnax Lab Ltd is principally engaged in the manufacturing and export of Pharmaceutical Formulations. Its product categories include Pharmaceuticals; Cosmetics; Herbal and Nutraceuticals. The company is developing and delivering Oral Formulations such as Cough Expectorants, Antacids, Anti-Histamines, Multi-Vitamins, Enzyme Preparations, Pediatric Formulations, Special Formulations for Geriatrics, Highly Viscous Products, Suspensions, and others.
69GF Score
Get the complete analysis for BOM:506128
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506128 has been successfully added to your 
